
Fabrice Jardin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5652392/publications.pdf Version: 2024-02-01



FARDICE LADDIN

#	Article	IF	CITATIONS
1	The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma. Blood, 2022, 139, 384-398.	1.4	29
2	Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas. Haematologica, 2022, 107, 755-758.	3.5	6
3	Sex-Biased <i>ZRSR2</i> Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis. Cancer Discovery, 2022, 12, 522-541.	9.4	44
4	Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical Hodgkin lymphoma: a retrospective study. Leukemia and Lymphoma, 2022, 63, 834-844.	1.3	8
5	Retrospective analysis of the safety of peripherally inserted catheters versus implanted port catheters during firstâ€line treatment for patients with diffuse large B ell lymphoma. European Journal of Haematology, 2022, 109, 41-49.	2.2	2
6	Comparison of bone marrow trephine sample quality between a drill-powered system and a manual needle system. Annals of Diagnostic Pathology, 2022, 59, 151952.	1.3	1
7	Integrative diagnosis of primary cutaneous large B-cell lymphomas supports the relevance of cell of origin profiling. PLoS ONE, 2022, 17, e0266978.	2.5	4
8	Controversies in the Interpretation of Liquid Biopsy Data in Lymphoma. HemaSphere, 2022, 6, e727.	2.7	2
9	Chemotherapy-free treatment in unfit patients aged 75 years and older with DLBCL: toward a new paradigm?. The Lancet Healthy Longevity, 2022, 3, e453-e454.	4.6	3
10	Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis. Blood Advances, 2021, 5, 1540-1551.	5.2	35
11	Outcomes after intensive care unit admission in newly diagnosed diffuse large Bâ€cell lymphoma patients: A realâ€life study. European Journal of Haematology, 2021, 106, 788-799.	2.2	4
12	Cell-Free DNA for the Management of Classical Hodgkin Lymphoma. Pharmaceuticals, 2021, 14, 207.	3.8	9
13	c-Rel Is the Pivotal NF-κB Subunit in Germinal Center Diffuse Large B-Cell Lymphoma: A LYSA Study. Frontiers in Oncology, 2021, 11, 638897.	2.8	7
14	Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older. Journal of Clinical Oncology, 2021, 39, 1203-1213.	1.6	39
15	Angiogenesis imaging study using interim [18F] RGD-K5 PET/CT in patients with lymphoma undergoing chemotherapy: preliminary evidence. EJNMMI Research, 2021, 11, 37.	2.5	3
16	cfDNA Sequencing: Technological Approaches and Bioinformatic Issues. Pharmaceuticals, 2021, 14, 596.	3.8	31
17	Pembrolizumab in the treatment of refractory primary mediastinal large B-cell lymphoma: safety and efficacy. Expert Review of Anticancer Therapy, 2021, 21, 941-956.	2.4	3
18	Concomitant occurrence of genetically distinct Hodgkin lymphoma and primary mediastinal lymphoma. Clinical Case Reports (discontinued), 2021, 9, e04504.	0.5	1

#	Article	IF	CITATIONS
19	A Molecular Classifier Increased the Accuracy of Lymphoma Diagnosis By Expert Pathologists in the Diffuse Large B-Cell Lymphoma Gained Trial from the Lysa. Blood, 2021, 138, 3495-3495.	1.4	0
20	XPO1E571K Mutation Modifies Exportin 1 Localisation and Interactome in B-Cell Lymphoma. Cancers, 2020, 12, 2829.	3.7	12
21	A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features. Clinical Cancer Research, 2020, 26, 3145-3153.	7.0	48
22	UMI-VarCal: a new UMI-based variant caller that efficiently improves low-frequency variant detection in paired-end sequencing NGS libraries. Bioinformatics, 2020, 36, 2718-2724.	4.1	18
23	Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study. Haematologica, 2020, 106, 154-162.	3.5	58
24	Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma. Blood Cancer Journal, 2020, 10, 59.	6.2	22
25	Correlations between baseline 18F-FDG PET tumour parameters and circulating DNA in diffuse large B cell lymphoma and Hodgkin lymphoma. EJNMMI Research, 2020, 10, 120.	2.5	10
26	Somatic mutations of cell-free circulating DNA detected by targeted next-generation sequencing and digital droplet PCR in classical Hodgkin lymphoma. Leukemia and Lymphoma, 2019, 60, 498-502.	1.3	24
27	Cell-free DNA and the monitoring of lymphoma treatment. Pharmacogenomics, 2019, 20, 1271-1282.	1.3	6
28	Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type. Journal of Investigative Dermatology, 2019, 139, 2334-2342.e8.	0.7	28
29	Improving R-CHOP in diffuse large B-cell lymphoma is still a challenge. Lancet Oncology, The, 2019, 20, 605-606.	10.7	11
30	A recurrent clonally distinct Burkitt lymphoma case highlights genetic key events contributing to oncogenesis. Genes Chromosomes and Cancer, 2019, 58, 595-601.	2.8	6
31	How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?. Blood Advances, 2019, 3, 4238-4251.	5.2	72
32	Cyclin D1-positive Mediastinal Large B-Cell Lymphoma With Copy Number Gains of CCND1 Gene. American Journal of Surgical Pathology, 2019, 43, 110-120.	3.7	15
33	Refining diffuse large B-cell lymphoma subgroups using integrated analysis of molecular profiles. EBioMedicine, 2019, 48, 58-69.	6.1	29
34	STAT6 is a cargo of exportin 1: Biological relevance in primary mediastinal B-cell lymphoma. Cellular Signalling, 2018, 46, 76-82.	3.6	15
35	Authors' Reply. Journal of Molecular Diagnostics, 2018, 20, 266.	2.8	0
36	Circulating tumor DNA: an important tool in precision medicine for lymphoma. Expert Review of Precision Medicine and Drug Development, 2018, 3, 11-21.	0.7	4

#	Article	IF	CITATIONS
37	Definition of a minimal genes set for mature lymphoid blood diseases. Hematologie, 2018, 24, 27-59.	0.0	4
38	Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. Lancet Haematology,the, 2018, 5, e403-e410.	4.6	21
39	Novel molecular classifications of DLBCL. Nature Reviews Clinical Oncology, 2018, 15, 474-476.	27.6	7
40	New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes. Oncotarget, 2018, 9, 28866-28876.	1.8	38
41	Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort. Blood Cancer Journal, 2018, 8, 74.	6.2	67
42	XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy. Journal of Hematology and Oncology, 2017, 10, 47.	17.0	62
43	The value of liquid biopsy in diagnosis and monitoring of diffuse large b-cell lymphoma: recent developments and future potential. Expert Review of Molecular Diagnostics, 2017, 17, 557-566.	3.1	18
44	ldentification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing. Journal of Investigative Dermatology, 2017, 137, 1984-1994.	0.7	93
45	Application of the cghRA framework to the genomic characterization of Diffuse Large B-Cell Lymphoma. Bioinformatics, 2017, 33, 2977-2985.	4.1	3
46	Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P–Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases. Clinical Cancer Research, 2017, 23, 2232-2244.	7.0	82
47	Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. Lancet Haematology,the, 2017, 4, e46-e55.	4.6	83
48	Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. New England Journal of Medicine, 2017, 377, 1250-1260.	27.0	313
49	Determination of Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification Classifier. Journal of Molecular Diagnostics, 2017, 19, 892-904.	2.8	39
50	Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay. Haematologica, 2017, 102, e404-e406.	3.5	16
51	Oncogenic events rather than antigen selection pressure may be the main driving forces for relapse in diffuse large Bâ€cell lymphomas. American Journal of Hematology, 2017, 92, 68-76.	4.1	8
52	ExportinÂ1 (or XPO1) abnormalities in hematological malignancies: from the gene to targeted therapy. Hematologie, 2017, 23, 43-56.	0.0	0
53	The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma. Oncotarget, 2017, 8, 8765-8774.	1.8	69
54	Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma. Oncotarget, 2017, 8, 48157-48168.	1.8	78

#	Article	IF	CITATIONS
55	Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large <scp>B</scp> â€cell lymphoma. Genes Chromosomes and Cancer, 2016, 55, 251-267.	2.8	75
56	Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B ell lymphoma. American Journal of Hematology, 2016, 91, 923-930.	4.1	79
57	Selecting radiomic features from FDG-PET images for cancer treatment outcome prediction. Medical Image Analysis, 2016, 32, 257-268.	11.6	59
58	Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma. Haematologica, 2016, 101, 1094-1101.	3.5	97
59	Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms. Blood, 2016, 127, 3040-3053.	1.4	60
60	Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study. Clinical Cancer Research, 2016, 22, 2919-2928.	7.0	181
61	Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2016, 57, 2171-2179.	1.3	69
62	Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma. Clinical Cancer Research, 2016, 22, 3801-3809.	7.0	151
63	The role of next-generation sequencing in understanding the genomic basis of diffuse large B cell lymphoma and advancing targeted therapies. Expert Review of Hematology, 2016, 9, 255-269.	2.2	12
64	MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. Blood, 2015, 126, 2466-2474.	1.4	212
65	Transfusion strategy in hematological intensive care unit: study protocol for a randomized controlled trial. Trials, 2015, 16, 533.	1.6	6
66	Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis. Haematologica, 2015, 100, e280-e284.	3.5	69
67	Body mass index and other anthropometric parameters in patients with diffuse large B-cell lymphoma: physiopathological significance and predictive value in the immunochemotherapy era. Leukemia and Lymphoma, 2015, 56, 1959-1968.	1.3	26
68	Accurate Classification of Germinal Center B-Cell–Like/Activated B-Cell–Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase–Multiplex Ligation-Dependent Probe Amplification Assay. Journal of Molecular Diagnostics, 2015, 17, 273-283.	2.8	50
69	Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era. Leukemia and Lymphoma, 2015, 56, 1213-1222.	1.3	29
70	Somatic Mutations Detected in Plasma Cell-Free DNA By Targeted Sequencing: Assessment of Liquid Biopsy in Primary Central Nervous System Lymphoma. Blood, 2015, 126, 332-332.	1.4	8
71	Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: Implications for targeted EZH2 inhibitor therapy?. Oncotarget, 2015, 6, 16712-16724.	1.8	32
72	Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large <scp>B</scp> â€cell lymphoma treated with immunochemotherapy. European Journal of Haematology, 2014, 93, 9-18.	2.2	100

#	Article	IF	CITATIONS
73	Young Patients With Non–Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma Benefit From Intensified Chemotherapy With ACVBP Plus Rituximab Compared With CHOP Plus Rituximab: Analysis of Data From the Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association Phase III Trial LNH 03-2B. Journal of Clinical Oncology, 2014, 32, 3996-4003.	1.6	79
74	Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leukemia and Lymphoma, 2014, 55, 817-823.	1.3	121
75	Rgb: a scriptable genome browser for R. Bioinformatics, 2014, 30, 2204-2205.	4.1	2
76	Targetable activating mutations are very frequent in GCB and ABC diffuse large B ell lymphoma. Genes Chromosomes and Cancer, 2014, 53, 144-153.	2.8	76
77	Next generation sequencing and the management of diffuse large B-cell lymphoma: from whole exome analysis to targeted therapy. Discovery Medicine, 2014, 18, 51-65.	0.5	28
78	Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2013, 54, 1898-1907.	1.3	36
79	Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2012, 53, 34-42.	1.3	40
80	The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica, 2011, 96, 1888-1890.	3.5	97
81	Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2011, 12, 460-468.	10.7	420
82	Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet, The, 2011, 378, 1858-1867.	13.7	311
83	<i>TET2</i> and <i>TP53</i> mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm. British Journal of Haematology, 2011, 153, 413-416.	2.5	79
84	Expression ofHYAL2 mRNA, hyaluronan and hyaluronidase in B-cell non-Hodgkin lymphoma: Relationship with tumor aggressiveness. International Journal of Cancer, 2005, 113, 207-212.	5.1	31
85	Adapted CHOP plus rituximab in non-Hodgkin's lymphoma in patients over 80 years old. Haematologica, 2005, 90, 1281-3.	3.5	26
86	Novel markers for determining risk and evaluation of minimal residual disease in diffuse large B-cell lymphoma. Annals of Lymphoma, 0, 1, 1-1.	4.5	0